Linked Life Data

15960557

Source:http://linkedlifedata.com/resource/pubmed/id/15960557

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-6-17
pubmed:abstractText
To develop a Markov model that allows the cost effectiveness of interventions in patients with chronic obstructive pulmonary disease (COPD) to be estimated, and to apply the model to investigate the cost effectiveness of an inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist (beta(2)-agonist) combination (salmeterol/fluticasone propionate) versus usual care.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1170-7690
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
619-37
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
pubmed:affiliation
Global Health Outcomes, GlaxoSmithKline Research & Development, Greenford, Middlesex, UK. michael.d.spencer@gsk.com
pubmed:publicationType
Journal Article